Breakthrough Therapy Designation

Key facts

Legal basis

Section 506(a) of the FD&C Act

Created by

Food and Drug Administration Safety and Innovation Act of 2012

Evidence needed

Preliminary clinical evidence on a clinically significant endpoint

FDA response time

Within 60 days of receiving the request

What is breakthrough therapy designation?

Breakthrough therapy designation identifies drugs whose early clinical data suggest a large step forward for patients with a serious condition. The improvement over available therapy must appear on one or more clinically significant endpoints.

The designation is not an approval and does not lower the evidence standard. A breakthrough drug must still meet the requirements for traditional or accelerated approval, and the FDA can rescind the designation if later data no longer support it.

Congress created the designation in the Food and Drug Administration Safety and Innovation Act of 2012 (FDASIA). Cell and gene therapies can also seek the similar Regenerative Medicine Advanced Therapy (RMAT) designation created by the 21st Century Cures Act of 2016.

How breakthrough designation works

A sponsor requests the designation with or after its Investigational New Drug (IND) application, ideally before the end-of-phase 2 meeting. If granted, it brings:

• All fast track features, including rolling review of the marketing application.
• Intensive FDA guidance on an efficient development program, beginning as early as Phase 1.
• An organizational commitment involving senior FDA managers.
• Eligibility for priority review and accelerated approval if the relevant criteria are met.

Why breakthrough designation matters

The designation is one of the clearest public signals that the FDA sees a drug as potentially practice-changing, and sponsors usually announce it. For competitive intelligence and pipeline analysis, it marks programs that often move faster and reach the market ahead of peers in the same indication.

Many requests are denied, and grants cluster in oncology and rare diseases. Because designation rests on early data, some breakthrough programs still fail in later trials, so it should be read as a signal of potential rather than a forecast of approval.